Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
$8.37
+0.8%
$11.05
$2.96
$40.37
$486.62M0.7210.86 million shs2.07 million shs
Invivyd, Inc. stock logo
IVVD
Invivyd
$0.79
+1.2%
$0.77
$0.53
$3.07
$231.53M0.814.01 million shs4.38 million shs
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
$32.89
+0.1%
$39.91
$8.91
$47.84
$2.07B2.18564,651 shs682,562 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
0.00%-10.96%+98.81%-67.56%+32.23%
Invivyd, Inc. stock logo
IVVD
Invivyd
0.00%-4.90%+14.55%+2.01%-39.11%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
0.00%-6.99%-17.73%-3.44%+238.03%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
$8.37
+0.8%
$11.05
$2.96
$40.37
$486.62M0.7210.86 million shs2.07 million shs
Invivyd, Inc. stock logo
IVVD
Invivyd
$0.79
+1.2%
$0.77
$0.53
$3.07
$231.53M0.814.01 million shs4.38 million shs
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
$32.89
+0.1%
$39.91
$8.91
$47.84
$2.07B2.18564,651 shs682,562 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
0.00%-10.96%+98.81%-67.56%+32.23%
Invivyd, Inc. stock logo
IVVD
Invivyd
0.00%-4.90%+14.55%+2.01%-39.11%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
0.00%-6.99%-17.73%-3.44%+238.03%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
2.18
Hold$29.15248.27% Upside
Invivyd, Inc. stock logo
IVVD
Invivyd
2.33
Hold$8.00918.46% Upside
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
2.63
Moderate Buy$48.1446.38% Upside

Current Analyst Ratings Breakdown

Latest KOD, IVVD, and CAPR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2026
Invivyd, Inc. stock logo
IVVD
Invivyd
UpgradeSell (E+)Sell (D-)
9/1/2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
UpgradeNeutralOverweight
8/27/2026
Invivyd, Inc. stock logo
IVVD
Invivyd
Reiterated RatingOverweight
8/25/2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
UpgradeMarket PerformOutperform
8/24/2026
Invivyd, Inc. stock logo
IVVD
Invivyd
DowngradeSell (D-)Sell (E+)
8/18/2026
Invivyd, Inc. stock logo
IVVD
Invivyd
Reiterated RatingBuy
8/17/2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
Reiterated RatingBuy$58.00
8/14/2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
UpgradeNeutralOverweight
8/3/2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
Boost Price TargetOverweight$56.00 ➝ $66.00
7/31/2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
DowngradeBuyHold
7/30/2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
DowngradeOverweightNeutral$2.00
(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
$22.27M21.85N/AN/A$5.53 per share1.51
Invivyd, Inc. stock logo
IVVD
Invivyd
$53.43M4.33N/AN/A$1.04 per share0.76
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/A$2.97 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
-$105.04M-$2.45N/AN/AN/AN/A-56.60%-43.97%11/9/2026 (Estimated)
Invivyd, Inc. stock logo
IVVD
Invivyd
-$52.49M-$0.33N/AN/AN/A-183.90%-59.73%-48.97%11/5/2026 (Estimated)
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$229.97M-$4.19N/AN/AN/AN/A-273.23%-85.48%11/12/2026 (Estimated)

Latest KOD, IVVD, and CAPR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
-$0.5889-$0.70-$0.1111-$0.70$2.08 millionN/A
8/13/2026Q2 2026
Invivyd, Inc. stock logo
IVVD
Invivyd
-$0.1067-$0.14-$0.0333-$0.14$14.40 million$14.29 million
8/12/2026Q2 2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$0.9565-$1.05-$0.0935-$1.05N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
N/AN/AN/AN/AN/A
Invivyd, Inc. stock logo
IVVD
Invivyd
N/AN/AN/AN/AN/A
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
N/A
7.35
7.35
Invivyd, Inc. stock logo
IVVD
Invivyd
N/A
5.87
5.87
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/A
2.49
2.49

Institutional Ownership

CompanyInstitutional Ownership
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
21.68%
Invivyd, Inc. stock logo
IVVD
Invivyd
70.36%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
89.06%

Insider Ownership

CompanyInsider Ownership
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
9.20%
Invivyd, Inc. stock logo
IVVD
Invivyd
12.25%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
44.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
10158.14 million52.79 millionOptionable
Invivyd, Inc. stock logo
IVVD
Invivyd
100294.76 million258.65 millionOptionable
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
12462.85 million34.94 millionOptionable

Recent News About These Companies

Microscope and test tubes beside a laptop showing a rising chart signal biotech progress and improving stock momentum.
3 Small-Cap Biotechs With Binary Catalysts on the Calendar
...
Squarepoint Ops LLC Boosts Position in Kodiak Sciences Inc. $KOD

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Capricor Therapeutics stock logo

Capricor Therapeutics NASDAQ:CAPR

$8.37 +0.07 (+0.84%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$8.40 +0.03 (+0.36%)
As of 09/11/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Invivyd stock logo

Invivyd NASDAQ:IVVD

$0.79 +0.01 (+1.24%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$0.80 +0.02 (+2.10%)
As of 09/11/2026 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Kodiak Sciences stock logo

Kodiak Sciences NASDAQ:KOD

$32.89 +0.02 (+0.06%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$33.50 +0.61 (+1.85%)
As of 09/11/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.